ALLMedicine™ Essential Thrombocytosis Center

Apr 30th, 2021 - Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?|2021|Spivak JL,|

Mar 5th, 2021 - Myeloproliferative neoplasms (MPNs) cause the over-production of blood cells such as erythrocytes (polycythemia vera) or platelets (essential thrombocytosis). JAK2 V617F is the most prevalent somatic mutation in many MPNs, but previous modeling of...

Feb 15th, 2021 - Percutaneous device closure was shown to effectively prevent recurrent strokes in patients with patent foramen ovale (PFO). Whether this protective effect is relevant for patients with hypercoagulable states (HCSs) is unknown as they were not repr...

Dec 5th, 2020 - Polycythemia vera, essential thrombocytosis (ET), and primary myelofibrosis (PMF) are grouped together as myeloproliferative neoplasms (MPNs) because of shared clinical, pathologic, and molecular features. The 2005 discovery of the driver mutation...

Nov 13th, 2020 - Patients reporting high PD-L1 expression have shown to respond well to immunotherapy; however, some patients develop hyperprogressive disease upon initiation of immune checkpoint inhibitors. We report a patient with lung cancer and 100% PD-L1 expr...

Oct 8th, 2015 - This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of CEP-701 (lestaurtinib) treatment at a dosage of 80 mg bid for 18 weeks (126 days) in patients with Polycythemia Vera (PV) who have abnormal baseline neut...

Apr 5th, 2011 - The purpose of this study is to evaluate the safety and tolerability of XL019 in adults with myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosp...

Jun 3rd, 2015 - The differential diagnosis of painful cutaneous ulcers in the setting of hematologic malignancy includes a variety of infectious and inflammatory etiologies such as ulcerative HSV, cytomegalovirus, Epstein-Barr virus, amoebic skin ulcerations, opp.

May 1st, 2014 - Conclusion This case describes a patient with two risk factors for CVT, a life-threatening condition. It should be considered in patients with ET and/or pregnant and postpartum patients presenting with headache or other neurological symptoms.

Sep 4th, 2013 - A 62-year-old white man with a past medical history of hypertension and essential thrombocytosis diagnosed 17 years ago presented at our institution. He was being treated with hydroxyurea, with which he required occasional blood transfusions and p.